Ibrutinib as Early Therapy in Chronic Lymphocytic Leukemia (CLL)

Clinical trial NCT03207555 · COMPLETED

Trial details

NCT number: NCT03207555
Sponsor: M.D. Anderson Cancer Center
Status: COMPLETED
Phase: Phase 2
Study type: INTERVENTIONAL

Malignant Neoplasms Stated as Primary Lymphoid Haematopoietic Chronic Lymphocytic Leukemia Small Lymphocytic Leukemia

Start date: 2018-05-23
Primary completion: 2024-08-02
Enrollment: 23

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.